Atrial fibrillation outcomes in patients from Asia and non-Asia countries: insights from GARFIELD-AF

作者：Chunyan Cheng, Tian‐Yu Lian, Xi‐Jie Zhu, Saverio Virdone, Kai Sun, A. John Camm, Xian-Mei Li, Shinya Goto, Karen S. Pieper, Gloria Kayani, Xianhong Fang, Zhi‐Cheng Jing, Ajay K. Kakkar · 发表于：Open Heart · 年份：2025 · DOI：10.1136/openhrt-2024-003109 · 被引用次数：13 · 研究领域：Atrial Fibrillation Management and Outcomes、Vitamin K Research Studies、Folate and B Vitamins Research

BACKGROUND: Differences in the clinical outcomes and level of risk among Asian versus non-Asian patients with atrial fibrillation (AF) have been sparsely investigated. OBJECTIVE: To provide a contemporary prospective comparison of outcomes for newly diagnosed patients with AF, between Asian and non-Asian regions. METHODS: Six Asian countries (China, Japan, India, Singapore, South Korea and Thailand) and 29 countries outside Asia participated in the Global Anticoagulant Registry in the FIELD-AF (GARFIELD-AF) study. Newly diagnosed patients with AF, enrolled between 2010 and 2016, were followed up for≥2 years. The outcome studies were all-cause, cardiovascular and non-cardiovascular mortality, non-haemorrhagic stroke/systemic embolism (SE), major bleeding. The association of geographical region with clinical outcomes (event rates per 100 person-years) were estimated using multivariable Cox models. RESULTS: -VASc≥2 excl. sex) were less frequently anticoagulated (60.1% vs 73.2%). Non-vitamin K oral anticoagulant (NOAC) was similar in both regions (∼28%), though Asian patients were more frequently underdosed. Both Asian and non-Asian patients who received NOAC at enrolment experienced lower all-cause mortality and non-haemorrhagic stroke/SE compared with patients on other treatments or none.All-cause mortality, non-cardiovascular mortality and major bleeding were less frequent in patients from Asia versus non-Asia (HR (95% CI): 0.62 (0.39 to 0.99), 0.52 (0.28 to 0.97), 0.58 (0.36 ...